Revance Presents Results of DaxibotulinumtoxinA for Injection in P-III ASPEN-1 Trial for the Treatment of Cervical Dystonia at AAN2021

April 2, 2021 Auto Bot Clinical Trials, Presents, results, Treatment 0

Shots:

  • The P-III ASPEN-1 trial evaluating the efficacy and safety of DaxibotulinumtoxinA (either 125 unit or 250 unit dose) for injection vs PBO in adults with cervical dystonia, patients followed for a maximum of 36 wks in post-treatment
  • The results showed median duration effect of up to 24 wks, as determined by time to loss of 80% peak treatment benefit, and has the potential to reduce frequency up to 50% annually, generally safe and well-tolerated
  • The trial underscores the potential of therapeutics pipeline for the treatment of muscle movement and pain disorders

Click here to­ read full press release/ article | Ref: BusinessWire | Image: Revance

The post Revance Presents Results of DaxibotulinumtoxinA for Injection in P-III ASPEN-1 Trial for the Treatment of Cervical Dystonia at AAN2021 first appeared on PharmaShots.